{"id":61870,"date":"2026-03-30T19:02:39","date_gmt":"2026-03-30T11:02:39","guid":{"rendered":"https:\/\/flcube.com\/?p=61870"},"modified":"2026-03-30T19:02:40","modified_gmt":"2026-03-30T11:02:40","slug":"jenscare-completes-first-in-human-study-of-ijensrobo-robot-assisted-tricuspid-valve-replacement-system","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61870","title":{"rendered":"Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System"},"content":{"rendered":"\n<p><strong>Jenscare Scientific Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9877:HKG\">HKG: 9877<\/a>), a pioneer in structural heart interventions, announced the successful completion of the <strong>first clinical study<\/strong> of its <strong>iJensRobo robot-assisted transcatheter tricuspid valve replacement (TTVR) system<\/strong>. Post-operative echocardiography confirmed <strong>complete resolution of tricuspid regurgitation with zero paravalvular leak<\/strong>, and the implanted <strong>LuX-Valve Plus prosthetic valve<\/strong> demonstrated <strong>secure anchoring and excellent hemodynamic stability<\/strong>. The milestone marks a critical step toward addressing one of cardiology\u2019s most challenging unmet needs: minimally invasive treatment for severe tricuspid regurgitation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-procedural-amp-clinical-outcomes\">Procedural &amp; Clinical Outcomes<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Outcome<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Tricuspid Regurgitation Post-Op<\/strong><\/td><td><strong>Resolved (Grade 0)<\/strong><\/td><\/tr><tr><td><strong>Paravalvular Leak<\/strong><\/td><td><strong>None detected<\/strong><\/td><\/tr><tr><td><strong>Valve Stability<\/strong><\/td><td>Securely anchored; no migration<\/td><\/tr><tr><td><strong>Device Used<\/strong><\/td><td>LuX-Valve Plus + iJensRobo robotic platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The case demonstrated the feasibility of <strong>robot-enhanced precision<\/strong> in a procedure historically limited by anatomical complexity and lack of dedicated devices.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ijensrobo-platform-engineering-innovation\">iJensRobo Platform: Engineering Innovation<\/h2>\n\n\n\n<p>The <strong>iJensRobo system<\/strong> integrates three core technologies to overcome traditional TTVR challenges:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High-Precision Motion Control<\/strong>: Sub-millimeter actuation enables fine adjustment during valve deployment<\/li>\n\n\n\n<li><strong>Active Safety Constraints<\/strong>: Real-time force feedback prevents excessive tissue trauma or device malposition<\/li>\n\n\n\n<li><strong>Intelligent Navigation<\/strong>: Fusion of fluoroscopy and 3D echocardiography guides catheter trajectory and valve orientation<\/li>\n<\/ul>\n\n\n\n<p>Unlike general-purpose surgical robots, iJensRobo is purpose-built for <strong>transcatheter structural heart interventions<\/strong>, offering cardiologists enhanced dexterity without abandoning percutaneous access.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-unmet-need\">Market Context &amp; Unmet Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tricuspid Regurgitation Burden<\/strong>: Affects <strong>>1.6 million patients in the U.S. and EU<\/strong>; severe cases carry <strong>>50% 1-year mortality<\/strong> if untreated<\/li>\n\n\n\n<li><strong>Therapeutic Gap<\/strong>: Few dedicated TTVR devices approved globally; most rely on off-label use or complex surgical repair<\/li>\n\n\n\n<li><strong>Jenscare\u2019s Edge<\/strong>: Combines its <strong>LuX-Valve Plus<\/strong>\u2014a self-expanding, non-circular valve designed for the tricuspid annulus\u2014with <strong>robotic delivery<\/strong>, potentially improving success rates over manual implantation<\/li>\n<\/ul>\n\n\n\n<p>This first-in-human result positions Jenscare at the forefront of <strong>robotic structural heart therapy<\/strong>, a nascent but high-growth segment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Acceleration<\/strong>: Data will support <strong>regulatory filings in China (NMPA)<\/strong> and <strong>CE Mark preparation<\/strong><\/li>\n\n\n\n<li><strong>Global Differentiation<\/strong>: One of only a handful of companies worldwide developing <strong>dedicated robotic TTVR systems<\/strong><\/li>\n\n\n\n<li><strong>Commercial Synergy<\/strong>: Leverages Jenscare\u2019s existing <strong>LuX-Valve franchise<\/strong> in pulmonary and tricuspid indications<\/li>\n<\/ul>\n\n\n\n<p>If scaled successfully, iJensRobo could become the <strong>standard platform for complex right-heart interventions<\/strong>, analogous to how robotics transformed mitral valve repair.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory pathways, clinical adoption, and technological scalability. Actual outcomes may vary due to trial expansion results, regulatory feedback, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033000132_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026033000132_c.\"><\/object><a id=\"wp-block-file--media-ce35e16d-a6ff-4cf3-bee9-c188c6a5e296\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033000132_c.pdf\">2026033000132_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033000132_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ce35e16d-a6ff-4cf3-bee9-c188c6a5e296\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jenscare Scientific Co., Ltd. (HKG: 9877), a pioneer in structural heart interventions, announced the successful&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[1300,583],"class_list":["post-61870","post","type-post","status-publish","format-standard","hentry","category-company","category-medical-device","tag-hkg-9877","tag-jenscare-scientific"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jenscare Scientific Co., Ltd. (HKG: 9877), a pioneer in structural heart interventions, announced the successful completion of the first clinical study of its iJensRobo robot-assisted transcatheter tricuspid valve replacement (TTVR) system. Post-operative echocardiography confirmed complete resolution of tricuspid regurgitation with zero paravalvular leak, and the implanted LuX-Valve Plus prosthetic valve demonstrated secure anchoring and excellent hemodynamic stability. The milestone marks a critical step toward addressing one of cardiology\u2019s most challenging unmet needs: minimally invasive treatment for severe tricuspid regurgitation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61870\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System\" \/>\n<meta property=\"og:description\" content=\"Jenscare Scientific Co., Ltd. (HKG: 9877), a pioneer in structural heart interventions, announced the successful completion of the first clinical study of its iJensRobo robot-assisted transcatheter tricuspid valve replacement (TTVR) system. Post-operative echocardiography confirmed complete resolution of tricuspid regurgitation with zero paravalvular leak, and the implanted LuX-Valve Plus prosthetic valve demonstrated secure anchoring and excellent hemodynamic stability. The milestone marks a critical step toward addressing one of cardiology\u2019s most challenging unmet needs: minimally invasive treatment for severe tricuspid regurgitation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61870\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-30T11:02:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-30T11:02:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61870#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61870\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System\",\"datePublished\":\"2026-03-30T11:02:39+00:00\",\"dateModified\":\"2026-03-30T11:02:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61870\"},\"wordCount\":399,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 9877\",\"Jenscare Scientific\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61870#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61870\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61870\",\"name\":\"Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-30T11:02:39+00:00\",\"dateModified\":\"2026-03-30T11:02:40+00:00\",\"description\":\"Jenscare Scientific Co., Ltd. (HKG: 9877), a pioneer in structural heart interventions, announced the successful completion of the first clinical study of its iJensRobo robot-assisted transcatheter tricuspid valve replacement (TTVR) system. Post-operative echocardiography confirmed complete resolution of tricuspid regurgitation with zero paravalvular leak, and the implanted LuX-Valve Plus prosthetic valve demonstrated secure anchoring and excellent hemodynamic stability. The milestone marks a critical step toward addressing one of cardiology\u2019s most challenging unmet needs: minimally invasive treatment for severe tricuspid regurgitation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61870#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61870\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61870#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System - Insight, China&#039;s Pharmaceutical Industry","description":"Jenscare Scientific Co., Ltd. (HKG: 9877), a pioneer in structural heart interventions, announced the successful completion of the first clinical study of its iJensRobo robot-assisted transcatheter tricuspid valve replacement (TTVR) system. Post-operative echocardiography confirmed complete resolution of tricuspid regurgitation with zero paravalvular leak, and the implanted LuX-Valve Plus prosthetic valve demonstrated secure anchoring and excellent hemodynamic stability. The milestone marks a critical step toward addressing one of cardiology\u2019s most challenging unmet needs: minimally invasive treatment for severe tricuspid regurgitation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61870","og_locale":"en_US","og_type":"article","og_title":"Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System","og_description":"Jenscare Scientific Co., Ltd. (HKG: 9877), a pioneer in structural heart interventions, announced the successful completion of the first clinical study of its iJensRobo robot-assisted transcatheter tricuspid valve replacement (TTVR) system. Post-operative echocardiography confirmed complete resolution of tricuspid regurgitation with zero paravalvular leak, and the implanted LuX-Valve Plus prosthetic valve demonstrated secure anchoring and excellent hemodynamic stability. The milestone marks a critical step toward addressing one of cardiology\u2019s most challenging unmet needs: minimally invasive treatment for severe tricuspid regurgitation.","og_url":"https:\/\/flcube.com\/?p=61870","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-30T11:02:39+00:00","article_modified_time":"2026-03-30T11:02:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61870#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61870"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System","datePublished":"2026-03-30T11:02:39+00:00","dateModified":"2026-03-30T11:02:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61870"},"wordCount":399,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 9877","Jenscare Scientific"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61870#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61870","url":"https:\/\/flcube.com\/?p=61870","name":"Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-30T11:02:39+00:00","dateModified":"2026-03-30T11:02:40+00:00","description":"Jenscare Scientific Co., Ltd. (HKG: 9877), a pioneer in structural heart interventions, announced the successful completion of the first clinical study of its iJensRobo robot-assisted transcatheter tricuspid valve replacement (TTVR) system. Post-operative echocardiography confirmed complete resolution of tricuspid regurgitation with zero paravalvular leak, and the implanted LuX-Valve Plus prosthetic valve demonstrated secure anchoring and excellent hemodynamic stability. The milestone marks a critical step toward addressing one of cardiology\u2019s most challenging unmet needs: minimally invasive treatment for severe tricuspid regurgitation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61870#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61870"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61870#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61870"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61870\/revisions"}],"predecessor-version":[{"id":61872,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61870\/revisions\/61872"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}